Petlife Pharmaceuticals, Inc.
PTLF · OTC
8/31/2017 | 8/31/2016 | 8/31/2015 | 8/31/2014 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $22 | $4 | $0 | $0 |
| SG&A Expenses | $22 | $4 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $23 | $4 | $2 | $1 |
| Operating Income | -$23 | -$4 | -$2 | -$2 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | $0 | $0 | $0 |
| Pre-Tax Income | -$23 | -$4 | -$2 | -$2 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$23 | -$4 | -$2 | -$2 |
| % Margin | – | – | – | – |
| EPS | -0.33 | -0.4 | -0.17 | -0.2 |
| % Growth | 17.5% | -135.3% | 15% | – |
| EPS Diluted | -0.33 | -0.4 | -0.17 | -0.2 |
| Weighted Avg Shares Out | 69 | 9 | 11 | 8 |
| Weighted Avg Shares Out Dil | 69 | 9 | 11 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$23 | -$4 | -$2 | -$2 |
| % Margin | – | – | – | – |